To include your compound in the COVID-19 Resource Center, submit it here.

Topical XEN402: Phase IIa data

A double-blind, crossover, U.S. Phase IIa trial in 56 patients showed that a

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE